PNAS: The team of Gao Guoquan of Zhongshan University found that metformin is effective against KRAS mutant colorectal cancer

For patients with metastatic colorectal cancer (mCRC), the overall survival rate was poor, especially in patients with KRAS tumor mutations, despite the use of Ilitocon or Osaliplatinum-based chemotherapy and combined anti-EGFR (epidermal growth factor receptor) drugmetformin as a potential new anti-tumor drug has been reported in many experiments, but its therapeutic activity is still unclear and controversialencouraging, our researchers found that the median survival time in patients with metformin was 37.8 months longer than in patients treated with the diabetes KRAS mutation-mCRC in combination with other sugar-lowering drugsin contrast, metformin did not improve the survival of patients with the wild KRAS gene mCRCinteresting is that metformin is preferred in KRAS-mutated mCRC cells in primary cell cultures and patient-derived xenocells, but not in wild cells, which is consistent with its significant efficacy in the mCRC of THE KRAS mutationthe mechanism of the mutated KRAS tumor protein high methylation, and inhibit the expression of multiple drugs and toxic compound exoplanet pump 1 (MATE1)MATE1 is a specific pump that discharges metformin from tumor cells by raising DNA methyl transferase 1 (DNMT1)therefore, the results provide evidence that patients with METC with the MUTATION of the KRAS gene benefit from metformin treatment, and that targeted MATE1 may provide a strategy to improve the anti-cancer response of metformin